Watch SUPN. Know when insiders buy.
One email the day a filing lands. Free.
SUPN
SUPERNUS PHARMACEUTICALS, INC.
41.21
−0.02 −0.05%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
22
FLAG · shorts 22
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.4BP/E —DIV YIELD —FCF YIELD 0.78%REV TTM $830.4M +24.9%NET INCOME −$109.9M −270.4%NET CASH $156.7M52W 37.88 – 57.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $219.1M | +32.4% | 84.6% | −$58M | −$58.4M | −359.4% | -1.01 | −$4.8M | $568K | −$5.4M | Aug 3 |
| Q1 2026 · Mar 31 | $207.7M | +38.6% | 88.7% | −$8.3M | −$2.3M | — | -0.04 | $66.5M | $0 | $66.5M | Aug 3 |
| Q4 2025 · Dec 31derived | $211.6M | +21.5% | 89.1% | −$3.9M | −$4.1M | −126.8% | -0.07 | $19.9M | $427K | $19.4M | Mar 2 |
| Q3 2025 · Sep 30 | $192.1M | +9.3% | 90.1% | −$60.2M | −$45.1M | −217.2% | -0.80 | −$61.7M | $129K | −$61.8M | Nov 6 |
| Q2 2025 · Jun 30 | $165.5M | −1.7% | 89.8% | $12.1M | $22.5M | +13.0% | 0.40 | $58.5M | $455K | $58.1M | Aug 3 |
| Q1 2025 · Mar 31 | $149.8M | +4.3% | 89.5% | −$10.3M | −$11.8M | −9637.9% | -0.21 | $30.6M | $327K | $30.3M | Aug 3 |
| Q4 2024 · Dec 31derived | $174.2M | +6.0% | 85.0% | $21.4M | $15.3M | +1204.5% | 0.27 | $44.4M | $213K | $44.2M | Mar 2 |
| Q3 2024 · Sep 30 | $175.7M | +14.2% | 90.0% | $40.8M | $38.5M | — | 0.69 | $53.5M | $200K | $53.3M | Nov 6 |
| Q2 2024 · Jun 30 | $168.3M | — | 89.4% | $22.6M | $19.9M | — | 0.36 | $35.6M | $64K | $35.6M | Nov 6 |
| Q1 2024 · Mar 31 | $143.6M | — | 88.6% | −$3.2M | $124K | — | 0.00 | $38.4M | $248K | $38.2M | Nov 6 |
| Q4 2023 · Dec 31derived | $164.3M | — | 88.1% | −$996K | $1.2M | — | 0.02 | $45M | −$36K | $45M | Mar 2 |
| Q3 2023 · Sep 30 | $153.9M | — | 87.3% | $8.1M | −$16M | — | -0.29 | $35.9M | $150K | $35.7M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $719M | 89.6% | −$62.3M | −$38.5M | -5.4% | -0.68 | $47.3M | $1.3M | $46M | — | — |
| FY2024 · to Dec 31 | $661.8M | 88.2% | $81.7M | $73.9M | 11.2% | 1.32 | $172M | $725K | $171.2M | — | — |
| FY2023 · to Dec 31 | $607.5M | 86.2% | −$5.3M | $1.3M | 0.2% | 0.02 | $111.1M | $551K | $110.5M | — | — |
| FY2022 · to Dec 31 | $667.2M | 86.9% | $46.1M | $60.7M | 9.1% | 1.04 | $116.8M | $412K | $116.4M | — | — |
| FY2021 · to Dec 31 | $579.8M | — | $86M | $53.4M | 9.2% | 0.98 | $127.1M | — | — | — | — |
| FY2020 · to Dec 31 | $520.4M | 89.9% | $173.7M | $127M | 24.4% | 2.36 | $138.4M | $3.4M | $134.9M | — | — |
Every number comes from SUPERNUS PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.